CJC-1295 & Ipamorelin: Growth Hormone Secretagogue Research Guide
Written by NorthPeptide Research Team | Reviewed December 23, 2025
Related Articles
Summary of Key Research References
| Study | Year | Type | Focus | Reference |
|---|---|---|---|---|
| Teichman et al. | 2006 | Clinical Trial | Prolonged GH and IGF-I stimulation by CJC-1295 in healthy adults | PMID 16352683 |
| Raun et al. | 1998 | Preclinical | Ipamorelin — the first selective growth hormone secretagogue | PMID 9849822 |
| Alba et al. | 2006 | Animal Study | CJC-1295 normalizes growth in GHRH knockout mouse | PMID 16822960 |
| Ionescu & Bhatt | 2006 | Clinical Trial | Pulsatile GH secretion persists during continuous CJC-1295 stimulation | PMID 17018654 |
| Sackmann-Sala et al. | 2009 | Clinical | CJC-1295 activates GH/IGF-1 axis — serum protein profile changes | PMC2787983 |
| Sigalos & Pastuszak | 2018 | Review | Growth hormone secretagogues in body composition management | PMC7108996 |
| Svensson et al. | 2017 | Review | The safety and efficacy of growth hormone secretagogues | PMC5632578 |
| Stanley et al. | 2019 | Animal Study | Ipamorelin efficacy on gastric dysmotility in postoperative ileus model | PMC4863553 |
For laboratory and research use only. Not for human consumption.
Explore NorthPeptide's research-grade CJC-1295 No DAC + Ipamorelin Blend — verified ≥98% purity with full COA documentation. View product details and COA →
Introduction to Growth Hormone Secretagogues
Growth hormone (GH) secretion from the anterior pituitary is regulated by two primary opposing signals: growth hormone-releasing hormone (GHRH), which stimulates GH release, and somatostatin, which inhibits it. This interplay produces the characteristic pulsatile pattern of GH secretion observed in humans, with the largest pulses occurring during deep sleep. A third regulatory pathway — the ghrelin/growth hormone secretagogue receptor (GHS-R) system — provides an additional stimulatory input that is mechanistically distinct from GHRH signaling.
CJC-1295 and Ipamorelin are synthetic peptides that act on these two separate stimulatory pathways. CJC-1295 is a modified GHRH analog, while Ipamorelin is a selective growth hormone secretagogue receptor agonist (ghrelin mimetic). Their combination has attracted significant research interest because the two peptides stimulate GH release through complementary mechanisms, and preclinical data suggests this combination may produce additive or synergistic effects on GH output while maintaining the natural pulsatile secretion pattern.
CJC-1295: A Modified GHRH Analog
Structure and Design
CJC-1295 is a synthetic analog of GHRH(1-29), the biologically active fragment of native growth hormone-releasing hormone. Native GHRH has a plasma half-life of approximately 7 minutes due to rapid enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV). CJC-1295 was designed to overcome this limitation through two key modifications:
- CJC-1295 with DAC (Drug Affinity Complex) — The original formulation incorporates a maleimidopropionic acid linker that enables covalent binding to serum albumin after injection. This albumin binding dramatically extends the half-life to approximately 6–8 days, creating sustained GH elevation. Available as CJC-1295 with DAC in our research catalog.
- CJC-1295 without DAC (Modified GRF 1-29) — Also known as Mod GRF(1-29) or tetrasubstituted GRF(1-29). This version incorporates four amino acid substitutions (Ala2, Ala8, Ala15, Leu27) that confer DPP-IV resistance without the albumin-binding complex. The resulting half-life is approximately 30 minutes — significantly longer than native GHRH but much shorter than the DAC version. Available as CJC-1295 No DAC.
Mechanism of Action
CJC-1295 acts as an agonist at the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary. Upon receptor binding, it activates the Gs-adenylyl cyclase-cAMP-PKA signaling cascade, which triggers GH synthesis and secretion. Key features of GHRH-R agonism include:
- Stimulation of GH release that is additive with endogenous GHRH pulses
- Subject to somatostatin inhibition — GH release is attenuated during somatostatin tone, preserving pulsatility
- Promotion of GH gene transcription and somatotroph proliferation with chronic administration
- Stimulation of IGF-1 production through downstream GH signaling
Clinical Research Data
A pivotal 2006 study published in the Journal of Clinical Endocrinology & Metabolism evaluated CJC-1295 with DAC in healthy subjects aged 21–61. Key findings included:
- A 2- to 10-fold increase in mean GH concentration that persisted for up to 6 days after a single subcutaneous injection
- Dose-dependent increases in IGF-1 levels of 1.5- to 3-fold, lasting 9–11 days
- Preservation of GH pulsatility — the normal pattern of GH peaks and troughs was maintained, with increased amplitude rather than constant elevation
- No significant changes in prolactin, cortisol, TSH, or other pituitary hormones at tested doses
The preservation of pulsatility is considered significant because continuous GH elevation (as opposed to pulsatile release) is associated with different downstream signaling and may lead to receptor desensitization over time.
Ipamorelin: A Selective Ghrelin Mimetic
Structure and Selectivity
Ipamorelin is a pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) that acts as a selective agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor activated by the endogenous hormone ghrelin. What distinguishes Ipamorelin from earlier GHS-R agonists such as GHRP-6 and GHRP-2 is its selectivity profile. Available as Ipamorelin in our research catalog.
In a head-to-head comparison study, Ipamorelin demonstrated:
- GH release comparable to GHRP-6 in potency
- No significant effect on ACTH or cortisol — unlike GHRP-6 and GHRP-2, which stimulate the hypothalamic-pituitary-adrenal (HPA) axis
- No significant effect on prolactin — unlike GHRP-6, which can increase prolactin levels
- No significant appetite stimulation — unlike GHRP-6, which activates ghrelin’s orexigenic (appetite-increasing) pathway
This selectivity profile made Ipamorelin the subject of particular interest in growth hormone research, as it enabled investigation of GHS-R-mediated GH release without the confounding effects on cortisol, prolactin, and appetite seen with less selective compounds.
Mechanism of Action
Ipamorelin binds to GHS-R1a receptors located on both pituitary somatotrophs and hypothalamic neurons. Its mechanism of GH stimulation is distinct from and complementary to the GHRH pathway:
- Pituitary action — Direct binding to GHS-R1a on somatotroph cells activates phospholipase C (PLC), increasing intracellular calcium and triggering GH vesicle exocytosis
- Hypothalamic action — Stimulates GHRH-releasing neurons in the arcuate nucleus, amplifying endogenous GHRH signaling
- Somatostatin antagonism — Functionally opposes somatostatin’s inhibitory tone, reducing the brake on GH secretion
The fact that Ipamorelin acts through a different receptor and intracellular signaling cascade than GHRH analogs provides the mechanistic basis for combination research with CJC-1295.
Clinical Research Data
Ipamorelin has been evaluated in several human clinical studies. A phase II clinical trial conducted by Helsinn Therapeutics investigated ipamorelin for postoperative ileus (delayed gut motility after abdominal surgery). While the trial focused on gastrointestinal effects rather than GH parameters, it provided human safety and pharmacokinetic data. The study documented dose-dependent GH release with a favorable safety profile and no clinically significant effects on cortisol, ACTH, or prolactin.
Additional human pharmacokinetic studies have characterized ipamorelin’s GH release profile as a rapid, high-amplitude pulse — peaking within 40 minutes of subcutaneous administration — followed by return to baseline within approximately 3 hours. This sharp pulsatile profile contrasts with the sustained elevation seen with CJC-1295 (DAC), which is relevant when considering combination protocols.
The CJC-1295 + Ipamorelin Combination
Rationale for Combination
The scientific rationale for combining CJC-1295 and Ipamorelin rests on the principle of dual-pathway stimulation of GH release. The two peptides activate different receptor systems with different intracellular signaling cascades:
| Parameter | CJC-1295 (No DAC) | Ipamorelin |
|---|---|---|
| Target receptor | GHRH-R | GHS-R1a |
| Signaling pathway | cAMP/PKA | PLC/IP3/Ca²⁺ |
| GH release pattern | Amplifies endogenous pulses | Initiates new pulse |
| Cortisol effect | None at standard doses | None (selective) |
| Prolactin effect | None | None (selective) |
| Appetite effect | None | Minimal |
| Half-life | ~30 min (no DAC) | ~2 hours |
Research on GHRH + GHS-R agonist combinations has consistently shown synergistic GH output — the combined response exceeds the sum of individual responses. This synergy has been documented with native GHRH + GHRP combinations in human studies, and the same principle is expected to apply to CJC-1295 + Ipamorelin based on their receptor pharmacology.
Advantages of the No DAC Version for Combination Research
When used in combination with Ipamorelin, CJC-1295 without DAC (Mod GRF 1-29) is generally preferred over the DAC version in research protocols. The shorter half-life of the no-DAC version allows for discrete pulsatile GH release that more closely mimics physiological secretion patterns. The DAC version’s sustained 6–8 day activity creates prolonged GH elevation that may lead to GH receptor downregulation and blunted IGF-1 response over time — a concern documented in extended-administration studies.
The CJC-1295 No DAC + Ipamorelin Blend is available for researchers investigating the combination.
Research Applications
The CJC-1295 + Ipamorelin combination has been investigated in research contexts including:
- Body composition studies — GH is a key regulator of lipolysis and lean mass maintenance. Research has examined whether combination GH secretagogue administration produces greater changes in body composition parameters than either agent alone.
- Age-related GH decline models — GH secretion decreases approximately 14% per decade after age 30. Combination secretagogues have been investigated as an approach to restoring GH pulsatility in aging models without exogenous GH administration.
- Recovery and tissue repair — Given GH’s documented role in collagen synthesis, tendon repair, and tissue remodeling, the combination has been investigated in healing models as an approach to support endogenous GH-dependent repair processes.
- Sleep architecture studies — The largest GH pulse occurs during slow-wave (deep) sleep. Research has investigated whether pre-sleep secretagogue administration augments this natural pulse and whether the enhanced GH release affects sleep quality parameters.
Comparison with Other GH Secretagogues
Understanding where CJC-1295 and Ipamorelin fit within the broader class of GH secretagogues helps contextualize their research applications.
GHRH Analogs
Sermorelin (GHRH 1-29) was the first GHRH analog approved for clinical use and remains the most extensively studied compound in this class. CJC-1295 was developed as a next-generation GHRH analog with improved pharmacokinetic properties — specifically, resistance to DPP-IV degradation that gives it a substantially longer half-life than sermorelin’s approximately 10-minute duration.
Tesamorelin is another modified GHRH analog that has received FDA approval for HIV-associated lipodystrophy. It incorporates a trans-3-hexenoic acid modification that extends its half-life, though not to the same degree as CJC-1295 with DAC.
GHS-R Agonists (Ghrelin Mimetics)
GHRP-2 and GHRP-6 are earlier-generation GHS-R agonists that were widely used in research before Ipamorelin’s development. Both are effective GH secretagogues but lack Ipamorelin’s selectivity — GHRP-6 notably increases appetite and prolactin, while GHRP-2 can elevate cortisol at higher doses. Hexarelin is another GHS-R agonist with potent GH release but less selectivity than Ipamorelin.
Selectivity Comparison
| Compound | GH Release | Cortisol | Prolactin | Appetite |
|---|---|---|---|---|
| Ipamorelin | +++ | — | — | Minimal |
| GHRP-2 | ++++ | + | + | Moderate |
| GHRP-6 | +++ | + | ++ | Strong |
| Hexarelin | ++++ | ++ | ++ | Moderate |
| Sermorelin | ++ | — | — | — |
| CJC-1295 (no DAC) | +++ | — | — | — |
Dosing in Research Models
The following table summarizes dosing parameters reported in published studies. These values are provided for research reference only and do not represent recommended doses for any application.
| Compound | Dose Range | Route | Timing |
|---|---|---|---|
| CJC-1295 with DAC | 30–60 μg/kg (single) | Subcutaneous | Once weekly |
| CJC-1295 no DAC | 1–2 μg/kg | Subcutaneous | 1–3× daily |
| Ipamorelin | 1 μg/kg (up to 100 μg/kg studied) | Subcutaneous / IV | 1–3× daily |
| Combination (no DAC + Ipam) | Per individual doses above | Subcutaneous | Pre-sleep or post-training |
Reconstitution and Handling
Both CJC-1295 and Ipamorelin are supplied as lyophilized powders requiring reconstitution with sterile bacteriostatic water before use in research.
- Storage — Lyophilized peptides at -20°C; reconstituted solutions at 2–8°C
- Reconstitution — Add bacteriostatic water slowly along the vial wall; do not agitate vigorously
- Stability — Reconstituted CJC-1295: approximately 20–30 days refrigerated. Reconstituted Ipamorelin: approximately 20–25 days refrigerated
- Combination vials — Pre-mixed blend products are reconstituted identically to single-peptide products
Safety Considerations in Research
Both CJC-1295 and Ipamorelin have demonstrated favorable safety profiles in clinical studies at research doses. Key safety observations include:
- Injection site reactions — Mild, transient erythema and induration at injection sites, reported in the CJC-1295 clinical study
- GH-related effects — At higher doses, effects consistent with elevated GH have been observed, including fluid retention, joint stiffness, and transient paresthesia
- No pituitary suppression — Unlike exogenous GH administration, secretagogue-stimulated GH release has not been shown to suppress endogenous GH production. The feedback mechanisms that regulate the GH axis remain intact because the pituitary itself produces the hormone in response to stimulation
- IGF-1 monitoring — Chronic GH elevation raises IGF-1 levels, and sustained supraphysiological IGF-1 has been associated with theoretical concerns in some research contexts. Monitoring IGF-1 as a biomarker is standard in GH secretagogue research protocols
Current Limitations and Future Directions
Despite substantial preclinical and clinical data for the individual peptides, several limitations characterize the current state of CJC-1295 + Ipamorelin combination research:
- Limited combination-specific clinical data — While both peptides have human data individually, published clinical trials specifically evaluating the combination are limited
- Long-term safety data — Extended-duration studies beyond several months are scarce for both individual peptides and particularly for the combination
- DAC vs. no DAC optimization — The optimal GHRH analog formulation for combination use remains an active area of investigation
- Individual variability — GH secretagogue responses vary considerably between individuals, influenced by age, body composition, endogenous GH status, and genetic factors
Future research directions include longer-term combination studies with body composition endpoints, investigation of optimal timing and dose ratios, and evaluation of secretagogue combinations in specific research populations such as aged or GH-deficient models.
Summary
CJC-1295 and Ipamorelin represent two of the most well-characterized growth hormone secretagogues in the research literature. CJC-1295 acts as a long-acting GHRH analog that amplifies endogenous GH pulses, while Ipamorelin is a selective ghrelin mimetic that initiates GH release through a complementary receptor pathway. Their combination exploits the well-documented synergy between GHRH and GHS-R stimulation to produce robust GH output while preserving physiological pulsatility and avoiding the cortisol, prolactin, and appetite effects associated with less selective compounds.
Browse our growth hormone secretagogue research peptides: CJC-1295 No DAC, Ipamorelin, CJC-1295 + Ipamorelin Blend, Sermorelin, and Tesamorelin.
Written by NorthPeptide Research Team
Ready to explore research-grade peptides?
This article is for informational and research purposes only. It does not constitute medical advice. All peptides sold by NorthPeptide are intended exclusively for laboratory and research use. Not for human consumption.